109 related articles for article (PubMed ID: 2500559)
41. Stimulation of creatine kinase activity in rat skeletal tissue in vivo and in vitro by protease-resistant variants of parathyroid hormone fragments.
Sömjen D; Vargas V; Waisman A; Wingender E; Tegge W; Kaye AM
Biochem J; 1995 Jul; 309 ( Pt 1)(Pt 1):85-90. PubMed ID: 7619087
[TBL] [Abstract][Full Text] [Related]
42. [Indications and prerequisites for bone biopsy].
Roth A; Abendroth K; Lehmann G
Z Orthop Unfall; 2012 Oct; 150(5):495-8. PubMed ID: 23076747
[TBL] [Abstract][Full Text] [Related]
43. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial.
Lane NE; Sanchez S; Modin GW; Genant HK; Pierini E; Arnaud CD
J Bone Miner Res; 2000 May; 15(5):944-51. PubMed ID: 10804025
[TBL] [Abstract][Full Text] [Related]
44. Coming to grips with bone loss.
Marx J
Science; 2004 Sep; 305(5689):1420-2. PubMed ID: 15353792
[No Abstract] [Full Text] [Related]
45. [Human parathyroid hormone (1-34) as a new therapeutic agent for osteoporosis].
Isogai Y
Clin Calcium; 2005 Jan; 15(1):18-24. PubMed ID: 15632468
[TBL] [Abstract][Full Text] [Related]
46. Cyclization by a specific lactam increases the ability of human parathyroid hormone (hPTH)-(1-31)NH2 to stimulate bone growth in ovariectomized rats.
Whitfield JF; Morley P; Willick G; Langille R; Ross V; MacLean S; Barbier JR
J Bone Miner Res; 1997 Aug; 12(8):1246-52. PubMed ID: 9258755
[TBL] [Abstract][Full Text] [Related]
47. Prevention of glucocorticoid-induced osteoporosis.
Saag KG
South Med J; 2004 Jun; 97(6):555-8. PubMed ID: 15255421
[TBL] [Abstract][Full Text] [Related]
48. Coherence therapy does not prevent axial bone loss in osteoporotic women: a preliminary comparative study.
Pacifici R; McMurtry C; Vered I; Rupich R; Avioli LV
J Clin Endocrinol Metab; 1988 Apr; 66(4):747-53. PubMed ID: 3126214
[TBL] [Abstract][Full Text] [Related]
49. Osteoporosis: how should it be treated?
Odvina CV
J Investig Med; 2006 Apr; 54(3):114-22. PubMed ID: 16948394
[TBL] [Abstract][Full Text] [Related]
50. [Treatment of Paget's disease with diphosphonate (disodium ethydronate)].
Caniggia A; Gennari C; Guideri R; Vattimo A; Nardi P
Minerva Med; 1976 Jan; 67(1):1-15. PubMed ID: 814505
[TBL] [Abstract][Full Text] [Related]
51. Osteoporosis-treating parathyroid hormone peptides: What are they? What do they do? How might they do it?
Whitfield JF
Curr Opin Investig Drugs; 2006 Apr; 7(4):349-59. PubMed ID: 16625822
[TBL] [Abstract][Full Text] [Related]
52. Intermittent Fugu parathyroid hormone 1 (1-34) is an anabolic bone agent in young male rats and osteopenic ovariectomized rats.
McManus JF; Davey RA; Maclean HE; Doust EA; Chiu WS; Sims NA; Bouxsein ML; Glatt V; Zajac JD; Danks JA
Bone; 2008 Jun; 42(6):1164-74. PubMed ID: 18387351
[TBL] [Abstract][Full Text] [Related]
53. Effect and safety of intermittent weekly administration of human parathyroid hormone 1-34 in patients with primary osteoporosis evaluated by histomorphometry and microstructural analysis of iliac trabecular bone before and after 1 year of treatment.
Miki T; Nakatsuka K; Naka H; Masaki H; Imanishi Y; Ito M; Inaba M; Morii H; Nishizawa Y
J Bone Miner Metab; 2004; 22(6):569-76. PubMed ID: 15490267
[TBL] [Abstract][Full Text] [Related]
54. Intermittent treatment with human parathyroid hormone (hPTH[1-34]) increased trabecular bone volume but not connectivity in osteopenic rats.
Lane NE; Thompson JM; Strewler GJ; Kinney JH
J Bone Miner Res; 1995 Oct; 10(10):1470-7. PubMed ID: 8686502
[TBL] [Abstract][Full Text] [Related]
55. A novel human parathyroid hormone (1-34) analog for the treatment of osteoporosis.
Feng J; Liu Y; Xing Y; Wang H; Li T; Liu J; Fan H; Cao R
Peptides; 2009 Jun; 30(6):1173-80. PubMed ID: 19463752
[TBL] [Abstract][Full Text] [Related]
56. [Treatment of Paget's disease of bone with ethane-1 hydroxy-1, 1 diphosphonate at low dosage (author's transl)].
Alexandre C; Chapuy MC; Bressot C; Vignon E; Arlot M; Mathieu L; Edouard C; Johnston CC; Meunier PJ
Nouv Presse Med; 1980 Nov; 9(45):3429-33. PubMed ID: 6777752
[TBL] [Abstract][Full Text] [Related]
57. [Role and possibilities of pathology in the diagnosis of osteoporosis].
Lintner F; Brand G; Böhm G
Wien Med Wochenschr; 1990 Oct; 140(18-19):462, 464. PubMed ID: 2251837
[TBL] [Abstract][Full Text] [Related]
58. The cancellous bone of the iliac crest.
Wakamatsu E; Sissons HA
Calcif Tissue Res; 1969; 4(2):147-61. PubMed ID: 5363270
[No Abstract] [Full Text] [Related]
59. Effects of dichloromethylene diphosphonate, ethane-1-hydroxy-1,1-diphosphonate, and rickets in rats.
O'Hara JP; Jowsey J; Williams GA
J Lab Clin Med; 1975 Nov; 86(5):793-802. PubMed ID: 171327
[TBL] [Abstract][Full Text] [Related]
60. Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) on the ultrastructure of parathyroid glands and plasma immunoreactive parathyroid hormone in pregnant cows fed a low calcium diet.
Yarrington JT; Capen CC; Black HE; Re R; Potts JT; Geho WB
Lab Invest; 1977 Apr; 36(4):402-12. PubMed ID: 191694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
